Microbot Medical Announces Brigham and Women's Hospital as a Site for its Pivotal Human Clinical Trial
17 Giugno 2024 - 2:30PM
Microbot Medical Inc. (Nasdaq: MBOT) today announces that Brigham
and Women’s Hospital (BWH), a leading academic medical center
located in Boston, Massachusetts, will participate as a clinical
trial site for the pivotal human clinical trial as part of its
Investigational Device Exemption (“IDE”) application for its
LIBERTY® Endovascular Robotic Surgical System. Dr. Dmitry Rabkin,
MD, PhD (Assistant Chief, Division of Angiography &
Interventional Radiology) has been selected as principal
investigator at BWH. “We are excited to participate in the clinical
evaluation of this innovative technology,” said Dr. Rabkin. BWH has
completed the Site Initiation Visit, during which BWH clinical
staff was trained on the clinical study protocols. In addition, a
shipment of LIBERTY investigational units arrived at BWH this week
for the clinical trial.
“We are pleased to work with Dr. Rabkin and the team at Brigham
and Women’s Hospital on this clinical study.” commented Harel
Gadot, CEO, President and Chairman of Microbot Medical. “We believe
their commitment to research and the advancement of science make
them an ideal clinical study site.”
The Company is in the process of engaging additional leading
centers to participate in the clinical trial.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
clinical- stage medical device company that specializes in
transformational micro-robotic technologies, with the goals of
improving clinical outcomes for patients and increasing
accessibility through the natural and artificial lumens within the
human body.
The Investigational LIBERTY® Endovascular
Robotic Surgical System aims to improve the way surgical robotics
are being used in endovascular procedures today, by eliminating the
need for large, cumbersome, and expensive capital equipment, while
reducing radiation exposure and physician strain. The Company
believes the LIBERTY® Endovascular Robotic Surgical System’s remote
operation has the potential to be the first system to democratize
endovascular interventional procedures.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions,
risks inherent in the development and/or commercialization of the
LIBERTY® Endovascular Robotic Surgical System, the outcome of its
studies to evaluate the LIBERTY® Endovascular Robotic Surgical
System, uncertainty in the results of pre-clinical and clinical
trials or regulatory pathways and regulatory approvals, including
whether the Company’s pivotal study in humans is successful, any
failure or inability to recruit physicians and clinicians to serve
as primary investigators to conduct regulatory studies which could
adversely affect or delay such studies, disruptions resulting from
new and ongoing hostilities between Israel and the Palestinians and
other neighboring countries, any lingering uncertainty resulting
from the COVID-19 pandemic, need and ability to obtain future
capital, and maintenance of intellectual property rights.
Additional information on risks facing Microbot Medical can be
found under the heading “Risk Factors” in Microbot Medical’s
periodic reports filed with the Securities and Exchange Commission
(SEC), which are available on the SEC’s web site at www.sec.gov.
Microbot Medical disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Investor Contact:
Michal Efraty
IR@microbotmedical.com
Grafico Azioni Microbot Medical (NASDAQ:MBOT)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Microbot Medical (NASDAQ:MBOT)
Storico
Da Set 2023 a Set 2024